S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Viela Bio Stock Price, Forecast & Analysis (NYSE:VIE)

-0.44 (-1.33 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
Now: $32.56
50-Day Range N/A
52-Week Range
Now: $32.56
Volume2,912 shs
Average Volume140,096 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.62 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive VIE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIE and its competitors with MarketBeat's FREE daily newsletter.

Viela Bio (NYSE:VIE) Frequently Asked Questions

What is Viela Bio's stock symbol?

Viela Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "VIE."

What price target have analysts set for VIE?

4 equities research analysts have issued 12-month target prices for Viela Bio's shares. Their forecasts range from $25.00 to $44.00. On average, they expect Viela Bio's stock price to reach $33.67 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for Viela Bio.

What is the consensus analysts' recommendation for Viela Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viela Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viela Bio.

Has Viela Bio been receiving favorable news coverage?

Media coverage about VIE stock has been trending very negative on Monday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viela Bio earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Viela Bio.

What other stocks do shareholders of Viela Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viela Bio investors own include NewMarket (NEU), FedEx (FDX), Cemex SAB de CV (CX), Arista Networks (ANET), Zumiez (ZUMZ), Zoom Video Communications (ZM), Regenxbio (RGNX), Oyster Point Pharma (OYST), Harmonic (HLIT) and Genocea Biosciences (GNCA).

Who are Viela Bio's key executives?

Viela Bio's management team includes the folowing people:
  • Dr. Zhengbin Yao, Chairman, Pres & CEO (Age 53)
  • Mr. Mitchell Chan, Chief Financial Officer (Age 38)
  • Dr. Aaron Ren M.B.A., Ph.D., VP and Head of Bus. Devel. & Operations (Age 42)
  • Ms. Kate Surdez, Head of HR
  • Dr. Jörn Drappa M.D., Ph.D., Chief Medical Officer and Head of R&D (Age 55)

When did Viela Bio IPO?

(VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

When does Viela Bio's lock-up period expire?

Viela Bio's lock-up period expires on Tuesday, March 31st. Viela Bio had issued 7,900,000 shares in its initial public offering on October 3rd. The total size of the offering was $150,100,000 based on an initial share price of $19.00. After the end of Viela Bio's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Viela Bio?

Shares of VIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Viela Bio's stock price today?

One share of VIE stock can currently be purchased for approximately $32.56.

How big of a company is Viela Bio?

Viela Bio has a market capitalization of $1.62 billion. Viela Bio employs 80 workers across the globe.View Additional Information About Viela Bio.

What is Viela Bio's official website?

The official website for Viela Bio is http://www.vielabio.com/.

How can I contact Viela Bio?

The company can be reached via phone at 240-558-0038.

MarketBeat Community Rating for Viela Bio (NYSE VIE)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Viela Bio and other stocks. Vote "Outperform" if you believe VIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel